For the quarter ending 2025-09-30, PCVX made $271,930K in revenue. -$212,830K in net income. Net profit margin of -78.27%.
| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Research and development | 209,933 | 194,179 | ||
| General and administrative | 32,447 | 32,040 | ||
| Total operating expenses | 242,380 | 226,219 | ||
| Loss from operations | -242,380 | -226,219 | ||
| Interest income | 29,259 | 31,073 | ||
| Other income | 291 | 28,573 | ||
| Total other income, net | 29,550 | 59,646 | ||
| Net loss | -212,830 | -166,573 | ||
| Net loss per share, basic (in dollars per share) | -1.56 | -1.22 | ||
| Net loss per share, diluted (in dollars per share) | -1.56 | -1.22 | ||
| Weighted-average shares outstanding, basic (in shares) | 136,196,512 | 136,033,746 | ||
| Weighted-average shares outstanding, diluted (in shares) | 136,196,512 | 136,033,746 | ||
Vaxcyte, Inc. (PCVX)
Vaxcyte, Inc. (PCVX)